Complete financial analysis of Portage Biotech Inc. (PRTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Portage Biotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kier Group plc (KIE.L) Income Statement Analysis – Financial Results
- Jungheinrich Aktiengesellschaft (JGHAF) Income Statement Analysis – Financial Results
- Speed Commerce, Inc. (SPDC) Income Statement Analysis – Financial Results
- Costain Group PLC (CSGQF) Income Statement Analysis – Financial Results
- Korea Refractories Co., Ltd (010040.KS) Income Statement Analysis – Financial Results
Portage Biotech Inc. (PRTG)
About Portage Biotech Inc.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.41K | 0.00 | 0.00 | 0.00 | 41.92K | 241.38K | 644.75K | 1.59M | 311.46K | 0.00 | 10.39K | 41.92K | 76.14K | 21.01K | 0.00 | 0.00 |
| Cost of Revenue | 54.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 956.97K | 0.00 | 0.00 |
| Gross Profit | -54.00K | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.41K | 0.00 | 0.00 | 0.00 | 41.92K | 241.38K | 644.75K | 1.59M | 311.46K | 0.00 | 10.39K | 41.92K | 76.14K | -935.96K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | -4,453.98% | 0.00% | 0.00% |
| Research & Development | 12.54M | 8.21M | 6.77M | 7.31M | 4.11M | 762.00K | 561.00K | 32.45M | 4.58M | 2.93M | 1.14M | 32.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 8.36M | 8.82M | 5.13M | 1.87M | 1.87M | 1.55M | 2.56M | 4.52M | 1.30M | 1.65M | 1.56M | 1.57M | 2.35M | 2.48M | 578.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.36K | 171.16K | 32.19K | 135.79K | 85.28K | 52.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.66M | 8.36M | 8.82M | 5.13M | 1.87M | 1.87M | 1.55M | 2.56M | 4.52M | 1.30M | 1.65M | 1.56M | 1.60M | 2.49M | 2.56M | 631.00K | 728.74K | 674.53K | 2.20M | 4.36M | 1.07M | 226.99K | 688.12K | 418.16K | 6.52K | 12.56K | 45.91K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.26M | 0.00 | 134.00K | 116.00K | 484.52K | 95.34K | 91.69K | -13.19K | -494.33K | 86.61K | 996.88K | 718.14K | -94.87K | 0.00 | 674.54K | 0.00 | 0.00 | 0.00 | 0.00 | 23.04K | 22.16K | 14.78K | 303.92K | 343.69K |
| Operating Expenses | 18.20M | 16.58M | 15.59M | 12.44M | 5.98M | 2.76M | 2.23M | 35.49M | 9.19M | 4.32M | 2.79M | 1.24M | 1.69M | 3.49M | 3.28M | 536.14K | 728.74K | 674.54K | 2.20M | 4.36M | 1.07M | 226.99K | 711.16K | 440.32K | 21.30K | 316.48K | 389.60K |
| Cost & Expenses | 18.25M | 16.58M | 15.59M | 12.44M | 5.98M | 2.76M | 2.23M | 35.49M | 9.19M | 4.32M | 2.79M | 1.24M | 1.69M | 3.49M | 3.28M | 536.14K | 728.74K | 674.54K | 2.20M | 4.36M | 1.07M | 226.99K | 711.16K | 440.32K | 978.27K | 316.48K | 389.60K |
| Interest Income | 274.00K | 217.00K | 43.00 | 177.00 | 11.00K | 111.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.26K | 71.21K | 0.00 | 26.68K | 1.33K | 191.42 | 0.00 | 0.00 | 9.76K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 32.00K | 9.00K | 43.00K | 177.00K | 557.00K | 88.00K | 32.00K | 552.42K | 7.38K | 20.04K | 3.35K | 2.18K | 1.75K | 4.21K | 677.91K | 1.87K | 1.58K | 0.00 | 3.46K | 3.24K | 2.83K | 0.00 | 1.08K | 6.15K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 54.00K | 1.00K | 15.59M | 12.24M | 5.98M | 2.69M | 168.00K | 168.00K | 9.19M | 1.22M | 1.16K | 1.74K | 2.25K | 2.50K | 2.26K | 1.61K | 793.74 | -456.33K | -167.06K | -128.54K | 35.81K | -986.52 | 23.04K | 22.16K | 14.78K | 12.18K | 11.48K |
| EBITDA | -18.20M | -15.78M | 0.00 | 0.00 | 0.00 | -650.00K | -2.07M | -35.33M | -5.00 | -4.32M | -6.63M | -1.47M | -2.48M | -3.71M | -3.30M | -492.61K | -553.15K | -489.70K | -2.34M | -4.01M | -1.04M | -216.60K | -646.20K | -342.01K | -942.48K | -304.29K | -378.12K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,253.29% | 0.00% | 0.00% | 0.00% | -1,056.00% | -144.48% | -75.95% | 291.64% | -1,405.74% | 0.00% | -2,171.73% | -1,157.15% | 508.28% | -4,485.01% | 0.00% | 0.00% |
| Operating Income | -18.25M | -16.58M | -15.59M | -12.44M | -5.98M | -2.76M | -2.23M | -35.49M | -9.19M | -4.32M | -6.30M | -1.44M | -2.47M | -3.89M | -3.17M | -544.11K | -487.35K | -33.37K | -3.93M | -4.05M | -1.07M | -216.60K | -669.24K | -364.18K | -957.26K | -316.50K | -396.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,467.70% | 0.00% | 0.00% | 0.00% | -1,297.89% | -201.90% | -5.18% | -246.88% | -1,299.75% | 0.00% | -2,084.05% | -1,596.47% | -478.28% | -4,555.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | -67.44M | -105.95M | 771.00K | -2.45M | -549.00K | -830.00K | 125.98M | -552.42K | -7.38K | -115.84K | -3.99M | -112.63K | -875.49K | 171.16K | -246.01K | -68.24K | -66.81K | 459.92K | -1.86M | 199.29K | 35.62K | 9.11K | -161.12K | -729.03K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -85.70M | -122.52M | -14.82M | -14.89M | -5.08M | -3.59M | 123.74M | -641.27K | -9.20M | -4.34M | -6.63M | -1.45M | -3.26M | -4.29M | -3.42M | -594.02K | -625.16K | 426.55K | -9.19M | -3.72M | -1.04M | -207.48K | -830.36K | -1.09M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,469.92% | 0.00% | 0.00% | 0.00% | -1,416.92% | -258.99% | 66.16% | -576.61% | -1,193.75% | 0.00% | -1,996.36% | -1,980.82% | -1,435.75% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -10.55M | -17.86M | 4.35M | 2.30M | 2.17M | -217.00K | -126.00M | -52.34M | -3.49M | -1.22M | 3.35K | 2.18K | 1.75K | -52.79K | 677.91K | 1.87K | 68.17K | 568.75K | 167.06K | 128.54K | -35.81K | 986.52 | 166.50K | 725.42K | 0.00 | 23.86 | 7.04K |
| Net Income | -75.34M | -104.61M | -19.17M | -17.19M | -7.25M | -2.64M | 123.74M | 16.30M | -5.71M | -3.12M | -6.30M | -1.45M | -2.48M | -3.84M | -3.85M | -545.98K | -555.52K | -142.20K | -4.10M | -4.18M | -1.04M | -217.58K | -835.74K | -1.09M | -957.26K | -316.50K | -396.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,469.92% | 0.00% | 0.00% | 0.00% | -1,302.35% | -230.14% | -22.06% | -257.58% | -1,342.06% | 0.00% | -2,093.54% | -1,993.66% | -1,431.00% | -4,555.34% | 0.00% | 0.00% |
| EPS | -3.70 | -6.49 | -1.47 | -1.47 | -0.66 | -0.55 | 46.21 | 6.42 | -2.38 | -1.61 | -3.89 | -1.77 | -3.15 | -4.88 | -8.97 | -1.81 | -1.93 | -0.52 | -26.01 | -35.55 | -28.31 | -21.08 | -118.28 | -168.85 | -165.44 | -103.87 | -251.36 |
| EPS Diluted | -3.70 | -6.49 | -1.47 | -1.47 | -0.66 | -0.55 | 45.89 | 5.99 | -2.38 | -1.61 | -3.89 | -1.77 | -3.15 | -4.88 | -8.97 | -1.81 | -1.93 | -0.52 | -26.01 | -35.55 | -28.31 | -21.08 | -118.28 | -168.85 | -165.44 | -103.87 | -251.36 |
| Weighted Avg Shares Out | 20.34M | 16.12M | 13.06M | 11.73M | 10.95M | 4.82M | 2.68M | 2.54M | 2.40M | 1.93M | 1.62M | 817.59K | 787.14K | 786.64K | 429.63K | 301.71K | 288.41K | 272.81K | 157.81K | 117.60K | 36.66K | 10.32K | 7.07K | 6.45K | 5.79K | 3.05K | 1.58K |
| Weighted Avg Shares Out (Dil) | 20.34M | 16.12M | 13.06M | 11.73M | 10.95M | 4.82M | 2.70M | 2.72M | 2.40M | 1.93M | 1.62M | 817.59K | 787.14K | 786.64K | 429.63K | 301.71K | 288.41K | 272.81K | 157.81K | 117.60K | 36.66K | 10.32K | 7.07K | 6.45K | 5.79K | 3.05K | 1.58K |
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results...
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and...
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
Portage Biotech Reports Business and Strategic Update
WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company's comprehensive review of its pipeline...
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
WESTPORT, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of...
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for...
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company's management team will participate in a...
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement...
Source: https://incomestatements.info
Category: Stock Reports